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 Drugs are used to have an effect on the body and, hopefully, this effect is beneficial.  The 
process of drugs altering things in the body is known as pharmacodynamics.  
Pharmacodynamics includes the mechanism of action of the drug, and the resulting actions in 
the body.  By knowing the mechanism of action of a drug, we can often predict the actions in 
the body, and the resulting clinical uses of a drug.  Also, by knowing the mechanism of a 
drug, we can often predict the adverse effects it will have. 
 
3.1. Pharmacodynamics – enzymes, ion channels, transporters and pumps 
3.1.1 Introduction to pharmacodynamics 
The two main branches of pharmacology are pharmacokinetics (“What the body does to the 
drug”) and pharmacodynamics (“What the drug does to the body”).  Drugs are administered 
to have a beneficial effect.  In order to have a beneficial effect, drugs need to cause changes 
in some of the body’s processes.  These can be a physiological, biochemical or pathological 
processes (Figure 3.1).   
 
 
Figure 3.1 Pharmacodynamics (Copyright QUT, Sheila Doggrell) 
 
The initial step in pharmacodynamics is the binding to distinct sites.  Although the body does 
not have any binding sites that were specifically designed for drug binding, it has lots of 
binding sites for endogenous compounds, and drugs can use these binding sites. 
 
3.1.2 Drug binding sites 
Drug binding sites exist on things like enzymes, ion channels, carriers, and receptors.  Thus, 
enzymes have binding sites that are usually intended for substrates of that enzyme.  The 
substrate binds to the enzyme, the enzymatic reaction takes place, and a product is produced 
(Figure 3.2).  Drugs can also bind to these sites to have an effect (Figure 3.2).  Mostly drugs 
bind to enzymes to inhibit their actions.  Thus, the substrate cannot be turned into the 





Figure 3.2 Drug and binding site on enzyme (Copyright QUT, Sheila Doggrell) 
 
Ion channels are pores in membrane that open and close to control the movement of ions, 
such as Na+, Ca2+, and K+, in and out of cells.  The movement of ions in and out of cells 
controls many physiological processes, and is regulated by binding sites.  Drugs can bind to 
these sites to enhance or inhibit the ionic movements (Figure 3.3). 
 
 
Figure 3.3 Drug and binding site on ion channel (Copyright QUT, Sheila Doggrell) 
 
Carriers can be divided into transporters and pumps.  Both of these carry endogenous 
substances across membranes.  Carriers have binding sites for their particular endogenous 
substance, and drugs may bind to this site, typically to inhibit the carrier (Figure 3.4).  For 
instance, if the activity of a carrier is enhanced in a pathological state, a drug can be used to 




Figure 3.4 Drug and transporter (Copyright QUT, Sheila Doggrell) 
 
Naturally occurring substances, such as neurotransmitters and hormones bind to specific 
receptive substances, which limits their effects to specific sites.  Over the years, specific 
receptive substance has been shortened to receptor.  Drugs can bind to receptors to have an 




Figure 3.5 Neurotransmitter, hormone, keys and receptors (Copyright QUT, Sheila Doggrell) 
 
If the drug mimics the effect of the naturally occurring substance at the receptor, the drug is 
known as an agonist.  The key fits the lock, and opens the door.  If the drug prevents the 
action of the endogenous substance, the drug is known as an antagonist.  In this case, the key 
had fitted into the lock but has not opened the door, but has prevented any other keys getting 
into the lock. 
 
After a receptor is stimulated by an endogenous substance, some intracellular processes occur 
that lead to the final action.  These intracellular processes are known as cell signaling.  Drugs 
can combine with components of the cell signaling to either enhance or inhibit the cell 
signaling, and hence the final action.  Examples of drugs that use all these different binding 
sites are discussed in turn. 
 
The final actions of a drug depend on the distribution of the binding sites.  Although we 
give drugs to have a beneficial effect, they may also have detrimental effects.  Both 
pharmacological and toxicological actions of drugs are dependent on the use of binding sites.  
Some endogenous compounds (some enzymes and some neurotransmitters) are widely 
distributed and have widespread binding sites.  Consequently, a drug that uses such binding 
sites will have widespread effects, and these could include beneficial and detrimental effects.  
In contrast, some enzymes and hormones are localised, and have localised binding sites.  
Drugs that bind to localised sites will have a local effect that is, hopefully, beneficial without 
any widespread detrimental effects. 
 
Another thing that helps localise the effects of drugs, is that there are subtypes of receptors.  
For instance, the receptor for noradrenaline and adrenaline in the body was originally known 
as adrenoreceptors, and has been shortened to adrenoceptors over the years.  However, 
noradrenaline and adrenaline do not have identical effects in the body, some are the same, 
some are different, and the only way this can be explained is by subtypes of receptors, 
initially α- and β-adrenoceptors (Figure 3.6). 
 
Figure 3.6 Subtypes of receptors (Copyright QUT, Sheila Doggrell) 
 
Further studies have shown that there are many adrenoceptor subtypes. Drugs that stimulate 
all the adrenoceptors will have widespread effects.  Drugs that select one adrenoceptor will 
have less widespread effects.  Noradrenaline and adrenaline stimulate all adrenoceptors to a 
certain degree, and have the potential to have widespread actions.  In contrast, drugs that 
select the subtypes, as selective agonists or selective antagonists may have localised actions.  
Selective means it has a greater effect at one receptor than others, it does not mean the drugs 
specifically stimulates one receptor. 
 
Although adrenoceptors are widespread, the lung has high amounts of one particular type of 
adrenoceptor, the 2-adrenoceptors.  Salbutamol is a selective 2-adrenoceptor agonist, and 
will have effects predominantly mediated by these receptor, including the 2-adrenoceptors of 
the lung.  Stimulation of the β2-adrenoceptors in the lung causes bronchodilation.  Thus, 
salbutamol is used as bronchodilator, which does not have all the other widespread effects 
observed with noradrenaline and adrenaline.   
 
Another example of this is the heart, which has high amounts of 1-adrenoceptors, and 
stimulation of the 1-adrenoceptors leads to an increase in heart rate and force.  Atenolol is 
a selective antagonist at 1-adrenoceptor, and acts to decrease heart rate and force, leading to 
a reduction in blood pressure.  Atenolol is used in the treatment of hypertension.  The effects 
of atenolol are predominantly limited to heart, and no widespread, potentially detrimental 
effects, are observed with atenolol.   
 
Receptors are not the only things that have subtypes.  There are subtypes of enzymes, ion 
channels, and carriers.  Drugs that are selective for one subtypes of an enzyme, ion channel, 




Enzymes have binding sites, and these are targets for drugs; typically drugs inhibit enzyme 
activity, and two examples of such drugs are discussed. 
 
3.1.3.1 Inhibition of acetylcholinesterase 
The first example is the drug neostigmine, which inhibits the enzyme acetylcholinesterase 
and is used in the treatment of myaesthenia gravis, an autoimmune disease.   
 
To understand how the drug works, it is necessary to understand the physiology and 
pathophysiology at the neuromuscular junction.  Every time I contract the muscles in my arm, 
I am activating my somatic (or voluntary) nervous system to release the neurotransmitter 
acetylcholine, Ach (Figure 3.7). 
 
Figure 3.7 Neuromuscular junction – physiological (Copyright QUT, Sheila Doggrell) 
 
The released acetylcholine activates receptors for acetylcholine on the muscle.  Like 
noradrenaline, acetylcholine has receptor sub-types, and the ones on the muscle are called 
nicotinic, as they can be stimulated by nicotine.  Stimulation of the nicotinic receptors leads 
to muscle activity, the contraction of the muscles.  However, it is difficult to keep the 
muscles contracted, as the action of acetylcholine is very short lived.  This is because, there is 
an enzyme, acetylcholinesterase, lurking, which breaks the acetylcholine down to acetate 
and choline.  The acetate and choline do not contract the muscle.  Thus, it is difficult to 
maintain a flexed arm. 
 
In myasthenia gravis, there is a loss of nicotinic receptors (Figure 3.8). 
 
Figure 3.8 Neuromuscular junction – myasthenia gravis (Copyright QUT, Sheila Doggrell) 
 
In myasthenia gravis, the nerves is working fine; it is still releasing acetylcholine, and the 
acetylcholine is still being broken down.  However, as there are reduced nicotinic receptors, 
there is reduced muscle activity.  The drug used to treat myasthenia gravis is neostigmine, 
which inhibits acetylcholinesterase to prevent the breakdown of acetylcholine (Figure 3.9). 
 
Figure 3.9 Neostigmine in myasthenia gravis (Copyright QUT, Sheila 
Doggrell) 
 
Inhibiting the breakdown of acetylcholine, leads to a build-up in the concentration of 
acetylcholine in the synapse, and this causes more stimulation of the existing nicotinic 
receptors.  The build-up of acetylcholine, in the absence of acetylcholinesterase, means that 
the acetylcholine can diffuse further from where it has been released, without breakdown, to 
reach other nicotinic receptors.  This restores muscular activity in myasthenia gravis.  
Myasthenia gravis is a rare disease, but drugs that act as enzyme inhibitors are also used in 
common disorders. 
 
3.1.3.2 Inhibition of cyclooxygenase 
For instance, cyclooxygenase is an enzyme involved in pain and fever, and the 
cyclooxygenase inhibitor paracetamol is used in the treatment of pain and fever.  Normally, 
we have low levels of free arachidonic acid as it is mostly stored as a component of the cell 
membrane (Figure 3.10). 
 
Figure 3.10 Activation of cyclooxygenase (Copyright QUT, Sheila Doggrell) 
 
Many stimuli, including bacterial infection can reverse this to cause the release of arachidonic 
acid (Figure 3.10).  Once released, arachidonic acid is readily metabolised to prostaglandins, 
in the presence of the widespread enzyme cyclooxygenase.  The prostaglandins are mediators 
of pain and fever. 
 
Paracetamol is a cyclooxygenase inhibitor (Figure 3.11). 
 
Figure 3.11 Mechanism of action of paracetamol 
 
Inhibition of the enzyme cyclooxygenase with paracetamol leads to reduced levels of 
prostaglandins, and consequently of the pain and fever mediated by prostaglandins. 
 
3.1.4 Ion channels 
 3.1.4.1 Introduction 
Another potential target for drug binding is ion channels.  Ion channels are protein pores 
(hole) in the lipid membrane that can be opened or closed, similar to a gate that can be 
opened or closed.  When an ion channel is closed, there is no ion transfer across the 
membrane.  In contrast, when the ion channel is open, the opening is small and only allows 
ions to flow.  When the channel is open, ions flow down their concentration gradient.  The 
movement of ions underlies many physiological processes.  Ion channels are specific for a 
species of ions (Na+ channels, K+ channels, Ca2+ channels), and there are also subtypes of ion 
channels.  Ion channels have binding sites on them that drugs can use to inhibit or enhance 
the movement of ions, to alter the physiological function of the ion channel. 
 
3.1.4.2 Inhibition of sodium channels 
A good example of how inhibiting a channel can change function is the blockage of sodium 
channels with local anaesthetics e.g. lignocaine.  When you have tissue damage, the afferent 
nerves are activated and a message is sent along the afferent (sensory) nerves to the brain, 
which originates the feeling of pain (Figure 3.12). 
 
   
Figure 3.12 Na+ channels and lignocaine (Copyright QUT, Sheila Doggrell) 
 
The pain message is carried along the nerve as part of the wave form known as the action 
potential.  The upstroke or depolarization phase of the action potential is due to sodium 
entering the nerve cell.  Na+ channel blockers, like lignocaine, block the Na+ channels, so 
there are no longer action potentials, and without this messenger there is no pain. 
 
3.1.5 Transporters 
  3.1.5.1 Introduction 
Another target at which drugs can bind as the first step in pharmacodynamics is carriers, such 
as transporters and pumps.  A transporter is like a bus; the endogenous compound hops on at 
one site (A) and is transported across a membrane to another site (B), where it hops off 
(Figure 3.13).  Transporters are involved in both pharmacokinetics and pharmacodynamics.  
Thus, in drug absorption, transporters are used to transport certain drugs across the 
membrane.  Thus, if Drug C has a similar structure to the endogenous compound, it may be 
transported across the membrane.   
 
With pharmacodynamics, we often use drugs to inhibit the transport of endogenous 
compound.  Thus, Drug D binds to the transporter, but is not transported.  However, by 




Figure 3.13 Drugs and transporters (Copyright QUT University, Sheila Doggrell) 
 
3.1.5.2 Inhibition of the serotonin transporter 
An important group of drugs that inhibit transporters are the antidepressants.  The 
biochemical cause of depression may be abnormal function of the neurotransmitters in the 
brain.  One of the main neurotransmitters implicated in depression is 5-hydroxytryptamine 
(5-HT), which is also known as serotonin.  One thing we do know about depression is that 
there is long-term effectiveness in depression of drugs that increase the levels of 5-HT in the 
brain. Inhibitors of the 5-HT transporter increase the levels of 5-HT in the synapses of the 
brain.   
 
To understand how this works, we first need to review the physiological process.  On 
activation of the nerve terminal, 5-HT is released, and then stimulates 5-HT receptors to have 
an effect (Figure 3.14).   
 
Figure 3.14 SERT transporter (Copyright QUT University, Sheila Doggrell) 
 
The action of 5-HT is short lived, as it is rapidly inactivated.  The 5-hydroxytryptamine (5-
HT) is inactivated by transport back into the neurone, on a transporter that is selective for 5-
HT, the SERT (the SERotonin Transporter).  When it is stored in nerve endings, with no 
access to its receptors, the 5-HT is inactive.  SERT is inhibited by Prozac (Fluoxetine).  This 
inhibits inactivation of 5-HT, and increases the levels of 5-HT in the synapse, with increased 
stimulation of receptor, and an increased effect. It takes a bit of time, but eventually raising 
the levels of 5-HT in the brain synapses has an antidepressant effect. 
 
 3.1.6 Pumps 
In addition to transporters, another form of carrier is a pump, which often actively pumps 
endogenous compounds from one site to another.  
 
  3.1.6.1 Inhibition of the proton pumps 
Probably, the best characterised pump is the proton pump.  Acid secretion, via the proton 
pump, in the stomach is required for normal digestion.  Dyspepsia (excessive acid secretion) 
is caused by bad cooking, overindulgence and anxiety, and can lead to acid-peptic disease.  In 
acid-peptic disease there is an imbalance between the aggressive factors of the disease, which 
are the acid, pepsin, and the bacteria Helicobacter pylori, and the protective factors, such as 
bicarbonate, mucus, and prostaglandins.  One way to restore the balance is to decrease the 
aggressive acid.   
 The proton pump is present on the parietal cells of the stomach, and is driven by the activity 
of an enzyme H+/K+ ATP-ase (Figure 3.15). 
 
Figure 3.15 The proton pump (Copyright QUT, Sheila Doggrell) 
 
The proton pump is stimulated by histamine, gastrin and acetylcholine.  Regardless of what is 
stimulating the pump, the pump is inhibited by proton pump inhibitors (PPIs).  This makes 
PPIs the most effective inhibitors of acid secretion.  Omeprazole is the prototype PPI. There 
are other drugs that have names ending with prazole, and these are all PPIs.   
 
The pharmacokinetic properties of the PPIs are interesting.  They are prodrugs, requiring 
activation in an acidic environment.  The only very acidic environment in the body is the 
stomach, and this is where the prazoles are activated, and this limits their action to the site, 




3.2. Pharmacodynamics – receptors and cell signaling  
3.2.1 Receptors 
One of the most important targets for drug binding is receptors.  These were originally known 
as specific receptive substance, which is a good description of what they do, they are 
specific receptive substance for individual endogenous compounds.  Over the years, this has 
been shortened to receptors.  There are receptors for many endogenous compounds, 
including hormones (endocrine and local), neurotransmitters, and growth factors.  Each 
receptor is specific for one endogenous compound, which is also known as the endogenous 
regulatory ligand, with endogenous meaning contained within body/physiological, and ligand 
meaning a naturally occurring substance that binds to receptor. 
 
Drugs that bind to receptors are either agonists or antagonists.  Agonists usually mimic the 
effect of the endogenous ligand.  In contrast, antagonists usually prevent the effect of the 
endogenous ligand. There are two main types of receptors.  The first involves G-protein-
coupled receptor (GPCR) signaling, and these are cell surface receptors that cross the cell 
membrane.  Endogenous substance binds to the receptor on the outside of the cell to cause a 
change inside the cell, which is the first step in the cell signaling leading to an effect.  GPCR 
signaling happens quickly (second/minutes), and is over quickly. For an ongoing effect, 
repeated stimulation of the receptor is needed.   
 
The second type of receptors is receptors regulating nuclear transcription.  To reach 
nuclear receptors, the endogenous compound must be able to cross the cell membrane. With 
nuclear receptors, the endogenous regulatory ligand binds to intracellular receptors, and the 
combination moves to the nucleus, and activates the first step in cell signaling leading to 
production of proteins.  Protein synthesis requires some time, so this type of receptor 
activation is slower, and has a longer time course.  Examples of these receptor types are 
discussed next. 
 
  3.2.1.1 G-protein coupled receptors 
Adrenaline is a hormone released from adrenal medulla that has widespread effects including 
stimulating bronchial GPC 2-adrenoceptors to induce bronchodilation via cell-signaling 
involving adenylate cyclise (Figure 3.16). 
 
Figure 3.16 GPCR – β2-adrenoceptor (Copyright QUT University, Sheila Doggrell) 
 
The β2-adrenoceptor spans the membrane.  This allows the adrenaline, which does not enter 
the cell, to talk to the inside of the cell.  The G proteins are so named as they require GTP 
(guanosine triphosphate) for action.  There are lots of different G proteins.  The one linked to 
the β2-adrenoceptor is stimulatory G-protein (Gs), and amplifies the message, leading to 
stimulation of a membrane bound enzyme, adenylate cyclase, which catalyses the conversion 
of ATP (adenosine triphosphate) to cAMP, which eventually leads to relaxation of the 
bronchial muscle, bronchodilation.   
 
Salbutamol is a selective agonist at β2-adrenoceptor.  Salbutamol does not mimic all the 
effects of adrenaline, just those mediated by β2-adrenoceptor.  This leads to the relaxation of 
bronchial smooth muscle, and salbutamol is used as a bronchodilator in asthma.  
 
3.2.1.2 Intracellular receptors 
An example of an intracellular receptor is the receptors for the glucocorticoids, which are the 
steroids produced by the adrenal cortex.  The physiological glucocorticoids, such as 
hydrocortisone (H) diffuse into cells.  The cells that are regulated by glucocorticoids have 
intracellular receptors (R) for glucocorticoids.  Stimulation of intracellular receptors leads 
to transcription of target genes (Tr), which modulate the proteins made be the cell (Figure 
3.17). 
 
Figure 3.17 Intracellular receptors (Copyright QUT, Sheila Doggrell) 
 
The physiological action of the glucocorticoids that pharmacologists are particular interested 
in is their anti-inflammatory actions.  These are not very pronounced with the physiological 
glucocorticoids, but changes to the glucocorticoid structure have produced more potent anti-
inflammatory agents.  Beclomethasone is a potent synthetic glucocorticoid that mimics the 
effects of hydrocortisone.  Beclomethasone is used as an anti-inflammatory agent in the 
treatment of asthma, where it is used to decrease the inflammation and reduce the likelihood 
of having an asthma attack. 
 
 3.2.2 Agonism 
3.2.2.1 Introduction to agonism and antagonism 
Salbutamol and beclomethasone are agonists at different receptor types.  Drugs that act at 
receptors can be either agonists or antagonists.  Two properties are used to characterize 
agonists and antagonists.  These are affinity and efficacy.  Affinity is the attraction of the 
drug for the receptor.  If a drug has high affinity, low concentrations of the drug bind to the 
receptor.  If a drug has low affinity, high concentrations of the drug are required to get any 
binding to the receptor.  If the drug has no affinity, no concentrations of the drug bind to the 
receptor.  The best drugs are the ones that have high affinity for their target receptor to 
initiate a beneficial effect, and little or no affinity for other receptors, so that they have as few 
unwanted effects as possible.  Both agonists and antagonists have affinity. 
 
Efficacy is also known as intrinsic activity or effect.   If a drug binds to receptor and has no 
effect, it has an efficacy of zero.  If a drug binds to receptor and, at the higher concentrations, 
can have the same maximum effect as the endogenous compound, it has an efficacy of 1.  
Agonists have efficacy, antagonists do not. 
 
To reiterate, agonists have affinity and efficacy (i.e. binds to receptor and have an effect) 
whereas antagonist has affinity but no efficacy (i.e. binds to receptor but does not have an 
effect alone).  Although receptor antagonists have no effects, they are important drugs as their 
binding prevents the binding of the endogenous compound and its effects. 
 
  3.2.2.2 Full and partial agonism 
There are several types of agonism including full and partial agonism, which are best 
understood from graphs.  In a graph of effect against long agonist concentration, a full 
agonist gives the same maximum response as the endogenous ligand, and has a nominally 
efficacy of 1 (Figure 3.18). 
 
Figure 3.18 Full and partial agonist (Copyright QUT, Sheila Doggrell) 
 
A partial agonist has a smaller maximum effect than the endogenous ligand or full agonist, 
and has an efficacy less than 1. 
 
An example of a partial agonist is buprenorphine.   Morphine stimulates opioid -receptors 
to induce analgesia, but another effect mediated by opioid -receptors is respiratory 
depression, which can occur with the higher concentrations of morphine.  Indeed, respiratory 
depression is a common side effect associated with full agonists at opioid -receptors.  
Buprenorphine is a partial agonist at opioid -receptors.  Buprenorphine causes analgesia but, 
as it has a lesser maximum effect; it is unlikely to cause any excessive respiratory depression.  
This means that buprenorphine can be a safer drug than morphine to use. 
 
3.2.2.3 Potency and selectivity of agonist 
Potency and selectivity are two other properties of agonists that are important in determining 
whether they will useful clinically.  Potency is measured as the half-maximal response to the 
drug being tested.  The parameter is known as the EC50, the concentration of agonist that 
causes have maximal response.  From the graph, the maximal response is determined, and for 
50% of that, the EC50 value is read off (Figure 3.19). 
 
Figure 3.19 Measuring agonist potency (Copyright QUT, Sheila Doggrell) 
 
Regardless of whether the agonist is a full agonist or a partial agonist, EC50 values are 
measured at half the maximal response to the agonist.  The lower the EC50 value, the more 
potent the agonist is.  In the Figure 8.5, the full agonist is more potent than the partial agonist, 
but it is possible to have partial agonists that are more potent than full agonists.  Clinically, 
potent agonists are usually preferable, especially if they are also selective. 
 
A drug that has a greater potency at receptor A than receptor B, is selective for receptor A, 
but is still capable of having effect at receptor B.  A drug that is potent at receptor A and has 
no effect at other receptors would be specific for receptor A, and would not be capable of 
having effects at other receptors.  Drugs are usually selective not specific. 
 
Potency and selectivity go hand in hand, and can be illustrated by comparing noradrenaline 
and isoprenaline.  Noradrenaline, the neurotransmitter released from the sympathetic 
nervous system, acts on cardiac 1-adrenoceptors to increase heart rate.  Isoprenaline is a 
synthetic drug that has a similar structure to noradrenaline. On the cardiac 1-adrenoceptors, 
isoprenaline is more potent (has a lower EC50) value than noradrenaline (Figure 3.20). 
 
Figure 3.20 Potency and selectivity at β1-adrenoceptors (Copyright QUT, Sheila Doggrell). 
 
Noradrenaline released from the sympathetic nervous system, also acts on vascular 1-
adrenoceptors to cause vasoconstriction.  At the vascular 1-adrenoceptors, isoprenaline is 
much less potent (has a higher EC50) value than noradrenaline (Figure 3.21). 
 
Figure 3.21 Potency and selectivity at α1-adrenoceptors (Copyright QUT, Sheila 
Doggrell) 
 
Taken together, these graphs show that noradrenaline does not select, but isoprenaline is 
selective for 1- over 1-adrenoceptors.  Thus, if we want to selectively mimic the effects 
of noradrenaline at 1-adrenoceptors, it is better to use isoprenaline than noradrenaline, as 
noradrenaline will have effects elsewhere, which could be detrimental effects.  Thus, 
isoprenaline was one of the first drugs used to mimic the effects of noradrenaline on the heart 
to increase heart force.  However, it is potent, which made it difficult to use.  Refinements of 
structure led to dobutamine, as a selective β1-adrenoceptor agonist, and dobutamine is used 
to increase heart force in the treatment of circulatory shock.  
 
3.2.3 Cell signaling 
Another potential target for drug binding is cell signaling.  When endogenous compounds 
bind to receptors, they initiate cell signaling that leads to the final action of the endogenous 
compound.  Drugs can bind to elements of the cell signaling to enhance or inhibit this 
process.  An example is with cell signaling on bronchial smooth muscle.  Adrenaline is the 
ligand for the β2-adrenoceptor, and when adrenaline is bound to the receptor, signaling 
involves activation of adenylyl cyclase (AC) to increase the levels of intracellular cAMP.  
There is more cell signaling, which eventually leads to relaxation of smooth muscle 
(bronchodilation) (Figure 3.22). 
 
Figure 3.22 Cell signaling (Copyright QUT, Sheila Doggrell) 
 
The effect of adrenaline stimulation is short-lived, as the action is terminated by the 
breakdown of cAMP in the presence of the intracellular enzyme phosphodiesterase.  
Aminophylline is a drug that modifies this cell signaling.  The mechanism of action of 
aminophylline is to inhibit the phosphodiesterase.  The resulting effects is an increased 
concentration of cAMP and, as cAMP levels dictate the degree of relaxation, increased 
relaxation of smooth muscle.  The clinical use of aminophylline is as a bronchodilator in 
bronchial asthma. 
 
 3.2.4 Antagonism 
  3.2.4.1 Competitive reversible 
In addition to acting at receptors to mimic the effects of endogenous compounds and initiate 
cell signaling, drugs can act at receptors as antagonist.  Receptor antagonists have affinity, 
but not efficacy; they have no effect on their own.  The most common type of receptor 
antagonism is competitive reversible.  Endogenous compounds and agonists (Ag) have 
readily reversible (electrostatic) binding to receptor (Figure 3.23). 
 
Figure 3.23 Competitive reversible antagonism I (Copyright QUT, Sheila Doggrell) 
 Competitive reversible antagonists have readily reversible binding to same site on receptor as 
the agonist.  Increasing the concentration of the antagonist, decreases the concentration of the 
agonist bound to the receptor, and the resulting effect.  Importantly, the effects of a 
competitive reversible antagonist can be overcome by increasing the concentration of the 
agonist, and this is useful in poisoning. 
 
Atenolol is an example of a competitive reversible antagonist.  Atenolol is a competitive 
reversible antagonist at 1-adrenoceptors, which means it has no effect alone (Figure 3.24).  
However, atenolol decreases the amount of noradrenaline (NA) bound to receptors, and this 
decreases the effect of noradrenaline.  On the heart, noradrenaline increases heart rate and 
force, and for any concentration of noradrenaline, atenolol will decrease the ability of 
noradrenaline to increase heart rate and force (Figure 3.24).   
 
Figure 3.24 Competitive reversible antagonism II (Copyright QUT, Sheila Doggrell) 
 
The graph shows that the higher the concentration of atenolol, the greater the inhibition of the 
response to noradrenaline.  Atenolol causes a parallel rightward shift of the noradrenaline 
concentration response, but if you add enough noradrenaline, a maximum response is 
obtained.  Atenolol is used clinically as an anti-hypertensive drug. 
 
  3.2.4.2 Functional 
Another type of antagonism is functional antagonism.  As always, the endogenous 
compounds and agonists (Ag) have readily reversible (electrostatic) binding to receptor 
(Figure 3.25).  The functional antagonist binds at site other than the receptor for the 
endogenous compound to inhibit the response.  This site could be the ion channel opened by 
stimulation of the receptor. 
 
Figure 3.25 Functional antagonism I (Copyright QUT, Sheila Doggrell) 
 An example of a functional antagonist is verapamil.  Verapamil is a Ca2+ channel blocker, 
and as such, a functional antagonist of responses mediated by cardiac 1-adrenoceptors.  
Activation of cardiac 1-adrenoceptors with noradrenaline leads to the opening of calcium 
channels, and an increase in intracellular calcium increases heart rate.  Verapamil reduces 
noradrenaline-induced increases in heart rate (Figure 3.26).  Graphically, with a functional 
antagonist, there is a non-parallel rightward shift of the concentration-response curves, often 
with a depression of the maximal response to the agonist. 
 
Figure 3.26 Functional antagonism II (Copyright QUT, Sheila Doggrell) 
 
Verapamil is used clinically to treat an overactive pacemaker. 
  
3.2.5 Anti-cancer drugs 
 
Anti-cancers drugs used to all be cytotoxic drugs, which mean they kill cells.  Unfortunately, 
this means that cytotoxic drugs kill normal cells as well as cancer cells, and the killing of 
normal cells will lead to adverse effects.   
 
  3.2.5.1 Cytotoxic anti-cancer drugs 
One of the characteristics, of cancers cells, is that they are very rapidly dividing, compared to 
most normal cells.  In the G1 phase of the cell cycle cells grow, and then in the S phase there 
is replication of the DNA (Figure 3.27).  After replication of the DNA, cells go through the 
G2 phase were they are preparing to divide.  The division is called mitosis (M), and you end 
up with 2 cells.  Any drug that interferes with this cell cycle will reduce the generation of 
new cells, including cancer cells. 
 
 
Figure 3.27 The cell cycle (Copyright QUT, Sheila Doggrell) 
 
Probably one of the best known cytotoxic drugs is cyclophosphamide.  Cyclophosphamide 
inhibits the cell cycle by preventing the production of RNA for the new cell.  
Cyclophosphamide is used in a variety of cancers, including leukemia and lymphoma.  As a 
cytotoxic drug, cyclophosphamide causes lots of adverse effects.  Severe bone marrow 
suppression can occur 1-2 weeks after treatment.  Cyclophosphamide can also cause anaemia 
and thrombocytopenia, and haemorrhagic cystitis.  Indeed the adverse effects with 
cyclophosphamide and other cytotoxic drugs are endless.  Cyclophosphamide can also cause 
nephrotoxicity, nausea and vomiting, gastrointestinal dysfunction, hair loss, impaired wound 
healing, darkening of skin, gonadal suppression (missed menstrual periods), cardiotoxicity 
etc. 
 
Thus, cytotoxic drugs are not the ideal anti-cancer drugs, as they kill normal cells, and that it 
would be better to have drugs that killed the cancer cells but not the normal cells.  This led to 
the idea of targeted anti-cancer drugs. 
 
3.2.5.2 Targeted anticancer drugs 
Targeted cancer medicines block the growth and spread of cancer by interfering with 
SPECIFIC molecules/cells involved in tumor growth and progression.  Why is this 
important?  Firstly, the drug maybe more effective, as it is will be preferentially killing the 
cancer cells.  Secondly, the drug may have less severe side effects if it is not killing all the 
normal cells.  Most importantly, it is possible that we can get a cure with some of the specific 
drugs 
 
One targeted approach is similar to a mechanism we have already discussed – enzyme 
inhibition. An activated enzyme, tyrosine kinase Bcr-Abl, underlies chronic myeloid 
leukaemia.  Thus, the obvious treatment for chronic myeloid leukaemia is to inhibit the 
tyrosine kinase Bcr-Abl.  This can be done with imatinib (Gleevec).  With imatinib, the 
response rate is about 70%, which means they get better, and if these subjects continue to 
take imatinib for several years, many are cured. 
 
Unfortunately, despite being developed to target an enzyme associated with the cancer, it 
does not mean that it is specific for that enzyme.  Thus, adverse effects do occur with 
imatinib, and these include gastrointestinal (pain, diarrhoea, nausea), fatigue, headache, and 
cardiotoxicity. 
 
Another approach to targeted anti-cancer drugs is monoclonal antibodies.  Monoclonal 
antibodies are similar to the endogenous antibodies produced by the body’s immune system 
to fight off bacteria and viruses.  They are made to specifically target and block a substance 
in the body or a specific cell type e.g. something specific to the cancer.  Usually, monoclonal 
antibodies are designed to recognise a specific protein on the surface of a cell (Figure 3.28). 
 
 
Figure 3.28 Monoclonal antibody (Copyright QUT, Sheila Doggrell) 
 
Trastuzumab is a monoclonal antibody to the HER2/neu receptor that is overexpressed in 
some breast cancers.  HER2 receptor overexpression leads to the rapid growth of breast 
cancer cells.  Trastuzumab improves survival in late-stage/metastatic HER2-positive breast 
cancers, but it does also have side effects.  Thus, trastuzumab is contraindicated in subjects 
with heart failure, and cardiac dysfunction is a major problem with the use of trastuzumab.   
 
Tumours need to have blood vessels in them to survive i.e. all cells need oxygen and nutrients 
delivered by blood vessels to function.  Vascular Endothelial Growth Factor A (VEGF-A) is 
required for blood vessel growth in tumours. Bevacizumab is a monoclonal antibody to 
VEGF-A which is used to prevent blood vessels developing in cancerous tumours.  
Bevacizumab is used in the treatment of colorectal, breast, renal and non-small cell lung 
cancers, especially in metastases.  Many of the common adverse effects are cardiovascular 
and may be related to inhibiting blood vessel growth as it will inhibit the growth of all blood 
vessels, not just those in tumours.  
 
